1 / Hvormed begrunder firmaet indikationen for bicalutamid, 150 mg, til lokalt avanceret prostatacancer på baggrund af den manglende statistisk signifikante fordel i total overlevelse og de betydelige bivirkninger?
1/ How does the company justify the indication of bicalutamide 150 mg for locally advanced prostate cancer knowing the absence of statistically significant overall survival and the important side effects?